We show that the day 21 purified CPs (GFPhigh population) maintain improved chondrogenic capacity over the course of 5 passages compared to controls. patient-specific or genetically-engineered cartilage for applications in drug screening for disease-modifying osteoarthritis drugs (DMOADs) [12]. Therefore, methods